Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.
Verve Therapeutics, a US-based cardiovascular disease drug developer with links to several institutions, is going public today in an upsized $267m initial public offering.
The offering consists of just over 14 million shares issued on the Nasdaq Global Select Market, increased from 11.8 million and priced at $19.00 each, above the $16 to $18 range set for the offering.
The IPO price values the spinout at approximately $876m. The company will list using the ticker symbol
